Nova EYE Medical Ltd (eye) Logo

Nova EYE Medical Ltd (EYE)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

EYE Chart

Snapshot

EYE's Principal Activity is the design, development, service and marketing, sales and distribution of medical devices to treat eye disease.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +16.87%
vs ASX 200 (1yr) -1.45%

Size

Market Capitalisation
ASX Rank 1,272 of 2,319
Sector Rank 111 of 199

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies PCK / TDL / BOT
EPS $0.256
DPS $0.00
NTA per share $0.18

Broker Consensus

EYE is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Nova Eye Medical Limited (EYE, formerly Ellex Medical Lasers Limited) is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices to diagnose and treat eye disease. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

Incorporation Details

Incorporated in SA on 11/05/1970 as Nartanda Pty Ltd. Name changed to Cowell Jade Pty Ltd on 22/07/1976. Converted to a public company on 16/12/1986. Name changed to Gemstone Corporation of Australia Ltd (GEC) on 04/01/1987; Ellex Medical Lasers Limited (ELX) on 31/07/2001.

Corporate Details

Head Office Kent Town SA 5067
Website www.nova-eye.com
Registry Computershare
Auditor PricewaterhouseCoopers
Date Listed 12 Sep 1994

Upcoming Calendar (Forecasted)

Date Event
24/02/2022 Report (Interim)
18/08/2022 Report (Prelim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
21/07/2020 $0.135 100% $0.1929 Interim 29/07/2020

See Upcoming Dividends for all ASX companies.

Key Data
DPS(TTM) $0.00
Gross DPS(TTM) $0.00
Dividend yield
Gross yield
Payout Ratio --
DRP No
DRP Features -

Directors & Management

Directors & Management

Name Title Since Bio
Mr Thomas (Tom) Anthony Spurling Non-Executive Director Aug 2020 Director Bio icon

Mr Thomas (Tom) Anthony Spurling

Non-Executive Director

Mr Spurling previously served as the Chief Executive Officer of Ellex Medical Lasers from 2011 to 2019. Tom has close to 30 years of senior executive experience serving in a range of commercial and management roles in Australia and the United States.

Mr Simon Gray Company Secretary Jun 2020
Mr Mike Southard Executive Director Jul 2018 Director Bio icon

Mr Mike Southard

Executive Director

Mr Southard has spent 26 years with the Alcon Laboratories of Fort Worth, Texas, as Vice President of the Global Surgical business. Prior to this, he was an Executive with Beecham Laboratories (now SmithKline Beecham), and Cooper-Vision, which was acquired by Alcon Laboratories. He is currently actively involved in Ophthalmology, Dermatology and Orthopaedics through his consulting company based in Portland, Oregon, USA. He has experience in both the International and US markets.

Mr Rahmon Coupe Non-Executive Director May 2013 Director Bio icon

Mr Rahmon Coupe

Non-Executive Director

Mr Coupe is Chief Executive Officer and Director of YourAmigo Limited, an organic search engine solutions company. Mr Coupe has more than 30 years of experience in the areas of corporate management, intellectual property management, contract negotiation, business development and engineering and has worked across a diverse range of industries, including information technology, life sciences and public broadcasting. Mr Coupe has held various project and engineering management roles for government research-based organisations, including the Defence Science and Technology Organisation (DSTO). He is a member of Risk Committee.

Mr Alexander Sundich Non-Executive Director Jul 2005 Director Bio icon

Mr Alexander Sundich

Non-Executive Director

Mr Sundich is currently a Director of Bridge Street Capital Partners, a corporate advisory and principal investment firm. From 2002 to 2008, Alex was a senior Executive in the funds management industry. Prior to this, he was an investment banker with Goldman Sachs and CSFB, involved in mergers and acquisitions and capital raisings. Alex is currently the Chairman of Petrel Energy Limited and Cleveland Mining Industry. He is chair of Risk committee.

Mr Victor Previn Executive Director,Executive Chairman Jul 2001 Director Bio icon

Mr Victor Previn

Executive Director,Executive Chairman

Mr Previn has more than 30 years experience in the laser industry. Mr Previn was responsible for developing and commercialising the technology platform that is now the core of the Company's current production. He has spent more than 3 decades in the ophthalmic laser industry travelling widely throughout Asia, Europe and the USA in a business development capacity. He is member of Risk committee.

Tom Spurling Group Executive N/A

Director Transactions

EYE directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
18/09/20 Thomas (Tom) Spurling Buy +20,000 $0.34 $6,800 On-market trade

Director Interests

The current holdings of EYE directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Mike Southard 30/06/2021 N/A 20,000 N/A N/A
Rahmon Coupe 30/06/2021 N/A 914,400 N/A N/A
Thomas (Tom) Spurling 30/06/2021 117,993 249,736 N/A N/A
Alexander Sundich 30/06/2021 N/A 6,300,000 N/A N/A
Victor Previn 30/06/2021 N/A 9,316,031 N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Jun 30, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
National Nominees Limited 28,078,147 19.54%
J P Morgan Nominees Australia Pty Limited 13,134,083 9.14%
Sedico Pty Ltd 7,266,980 5.06%
Bond Street Custodians Limited 6,081,275 4.23%
Ruminator Pty Ltd 5,062,008 3.52%
Pine Street Pty Ltd <Pine Street Super Fund A/C> 3,400,000 2.37%
Canala Super Fund Pty Ltd 3,258,173 2.27%
Altor Capital Management Pty Ltd 2,382,778 1.66%
Citicorp Nominees Pty Limited 2,296,006 1.60%
Pine Street Pty Ltd 1,900,000 1.32%
Sedico Pty Ltd <Victor Previn Superfund A/C> 1,200,000 0.84%
Neweconomy Com Au Nominees Pty Limited 1,109,010 0.77%
Pine Street Pty Ltd (i) 1,000,000 0.70%
Five Talents Limited 963,607 0.67%
BNP Paribas Nominees Pty Ltd Acf Clearstream 930,441 0.65%
HSBC Custody Nominees (Australia) Limited 928,526 0.65%
Mr Douglas Robert Buchanan + Mrs Robyn Lorraine Buchanan 925,000 0.64%
Mr Rahmon Charles Coupe + Mrs Julia Deborah Coupe 874,400 0.61%
Dr Peter Anthony Stewart 754,834 0.53%
Nurragi Investments Pty Ltd 699,000 0.49%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 1,268 939 461 896 135 3,699

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
National Nominees Limited 30/06/2021 28,078,147 19.54
Sedico Pty Ltd 30/06/2021 7,266,980 5.06
JP Morgan Nominees Australia Limited 30/06/2021 13,134,083 9.14
Natioanl Nominees (Australian Ethical Investment) 27/07/2021 27,585,007 19.20

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
27-07-21 Natioanl Nominees (Australian Ethical Investment) 2,391,383 17.53 19.20
28-04-21 Natioanl Nominees (Australian Ethical Investment) 1,629,400 16.40 17.53
10-12-20 Natioanl Nominees (Australian Ethical Investment) 1,570,312 15.32 16.40

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
EYE Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.